These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36195132)

  • 1. Ritonavir Form III: A New Polymorph After 24 Years.
    Yao X; Henry RF; Zhang GGZ
    J Pharm Sci; 2023 Jan; 112(1):237-242. PubMed ID: 36195132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritonavir Revisited: Melt Crystallization Can Easily Find the Late-Appearing Polymorph II and Unexpectedly Discover a New Polymorph III.
    Li S; Liu B; Chen Z; Ou X; Rong H; Lu M
    Mol Pharm; 2023 Aug; 20(8):3854-3863. PubMed ID: 37450774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir: an extraordinary example of conformational polymorphism.
    Bauer J; Spanton S; Henry R; Quick J; Dziki W; Porter W; Morris J
    Pharm Res; 2001 Jun; 18(6):859-66. PubMed ID: 11474792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old Polymorph, New Technique: Assessing Ritonavir Crystallinity Using Low-Frequency Raman Spectroscopy.
    Hatipoglu MK; Zaker Y; Willett DR; Gupta N; Rodriguez JD; Patankar S; Capella P; Yilmaz H
    Anal Chem; 2023 Oct; 95(41):15325-15332. PubMed ID: 37796650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapsone Form V: A Late Appearing Thermodynamic Polymorph of a Pharmaceutical.
    Braun DE; Vickers M; Griesser UJ
    Mol Pharm; 2019 Jul; 16(7):3221-3236. PubMed ID: 31075201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties.
    Wang C; Rosbottom I; Turner TD; Laing S; Maloney AGP; Sheikh AY; Docherty R; Yin Q; Roberts KJ
    Pharm Res; 2021 Jun; 38(6):971-990. PubMed ID: 34009625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a new polymorph of clotrimazole through melt crystallization: Understanding nucleation and growth kinetics.
    Zhang J; Liu M; Xu M; Chen Z; Peng X; Yang Q; Cai T; Zeng Z
    J Chem Phys; 2023 Jan; 158(3):034503. PubMed ID: 36681648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Solvent Selection on the Crystallizability and Polymorphic Selectivity Associated with the Formation of the "Disappeared" Form I Polymorph of Ritonavir.
    Wang C; Ma CY; Hong RS; Turner TD; Rosbottom I; Sheikh AY; Yin Q; Roberts KJ
    Mol Pharm; 2024 Jul; 21(7):3525-3539. PubMed ID: 38900600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Crystal Nuclei on Dissolution of Amorphous Drugs.
    Yao X; Yu L; Zhang GGZ
    Mol Pharm; 2023 Mar; 20(3):1796-1805. PubMed ID: 36749110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PH-induced nanosegregation of ritonavir to lyotropic liquid crystal of higher solubility than crystalline polymorphs.
    Rodríguez-Spong B; Acciacca A; Fleisher D; Rodríguez-Hornedo N
    Mol Pharm; 2008; 5(6):956-67. PubMed ID: 19434919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization.
    Morissette SL; Soukasene S; Levinson D; Cima MJ; Almarsson O
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2180-4. PubMed ID: 12604798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorph selection during the crystallization of Yukawa systems.
    Desgranges C; Delhommelle J
    J Chem Phys; 2007 Feb; 126(5):054501. PubMed ID: 17302479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism in molecular solids: an extraordinary system of red, orange, and yellow crystals.
    Yu L
    Acc Chem Res; 2010 Sep; 43(9):1257-66. PubMed ID: 20560545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the Impact of Chitosan on the Nucleation and Crystal Growth of Ritonavir from Supersaturated Solutions.
    Budiman A; Kalina K; Aristawidya L; Shofwan AAA; Rusdin A; Aulifa DL
    Polymers (Basel); 2023 Mar; 15(5):. PubMed ID: 36904523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of liquid polymorphism during the crystallization of silicon.
    Desgranges C; Delhommelle J
    J Am Chem Soc; 2011 Mar; 133(9):2872-4. PubMed ID: 21322596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates.
    Mitchell CA; Yu L; Ward MD
    J Am Chem Soc; 2001 Nov; 123(44):10830-9. PubMed ID: 11686684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural analysis of polymorphism and solvation in tranilast.
    Vogt FG; Cohen DE; Bowman JD; Spoors GP; Zuber GE; Trescher GA; Dell'orco PC; Katrincic LM; Debrosse CW; Curtis Haltiwanger R
    J Pharm Sci; 2005 Mar; 94(3):651-65. PubMed ID: 15666296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new high-pressure benzocaine polymorph - towards understanding the molecular aggregation in crystals of an important active pharmaceutical ingredient (API).
    Patyk-Kaźmierczak E; Kaźmierczak M
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2020 Feb; 76(Pt 1):56-64. PubMed ID: 32831241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and physicochemical characterization of caffeine-citric acid co-crystal polymorphs.
    Mukaida M; Watanabe Y; Sugano K; Terada K
    Eur J Pharm Sci; 2015 Nov; 79():61-6. PubMed ID: 26360836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
    Erdemir D; Lee AY; Myerson AS
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.